Published in Gene Therapy Weekly, March 2nd, 2006
"Despite the existence for some time of effective prophylactic vaccines, HBV infection remains an important global concern. Improvements on existing vaccines could be beneficial, especially in situations where it is desirable or necessary to induce protective immunity more rapidly or with fewer doses," wrote P.J. Payette and colleagues, Coley Pharmaceutical Canada.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.